Heuron ICH
AI-powered triage and notification for intracranial hemorrhage detection
Software · On PremiseCompany source
Company profile
About Heuron Co.
Heuron Co. is a South Korean medical imaging AI company that develops computer-aided diagnostic software for healthcare providers. The company's flagship products include Heuron IPD, an AI-powered diagnostic aid for neurodegenerative Parkinson's disease that analyzes nigrosome 1 MR images, and Heuron ICH, a radiological triage and notification system for intracranial hemorrhage detection. Heuron's solutions are designed to assist medical professionals in streamlining clinical workflows and improving diagnostic accuracy through objective, AI-driven insights. The company's technology analyzes medical imaging data combined with clinical information to support healthcare decision-making. Heuron IPD has demonstrated high performance with sensitivity ≥93.3% and specificity ≥95% in internal evaluations. The company maintains strict compliance with healthcare data protection regulations and deploys its solutions through cloud infrastructure. Heuron serves hospitals, radiology departments, and neurology specialists, providing tools that integrate into existing clinical workflows to enhance diagnostic capabilities and patient care outcomes.
Company description Heuron Co. official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Heuron Co.?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Intracranial hemorrhage (ICH)
- Neurodegenerative Parkinson's disease
Who it serves
- Hospitals
- Medical professionals
- Neurology specialists
- Radiology departments
Deployment & integration
On Premise deployment with recorded integration context.
Geographic context
MarketsSouth Korea
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Heuron IPD
AI-powered diagnostic aid for Parkinson's disease detection
Software · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Neuromelanin-sensitive MRI for identifying dopamine transporter imaging abnormality risk in idiopathic rapid eye movement sleep behavior disorder.Brain imaging and behavior · Jul 6, 2026
Neuromelanin imaging outperforms free water imaging in diagnosing early Parkinson's disease: a comparative MRI study.NPJ Parkinson's disease · Feb 13, 2026
Using a Deep Learning-Based Decision Support System to Predict Emergent Large Vessel Occlusion Using Non-Contrast Computed Tomography.Journal of clinical medicine · Jun 30, 2025
Deep Learning-Based Algorithm for Automatic Quantification of Nigrosome-1 and Parkinsonism Classification Using Susceptibility Map-Weighted MRI.AJNR. American journal of neuroradiology · May 2, 2025
Economic value of AI-based MRI triage for Parkinson's disease: a cost-benefit study in South Korea and the United States.Frontiers in public health · Jan 1, 2025
A human brain atlas of χ-separation for normative iron and myelin distributions.NMR in biomedicine · Dec 1, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Heuron ICHK233247 · 510k · May 15, 2024
Veuron-Brain-pAb3K231642 · 510k · Oct 13, 2023
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Sensitivity ≥93.3%
Heuron IPD for Parkinson's disease diagnosis
Specificity ≥95%
Heuron IPD for Parkinson's disease diagnosis
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
송수화
개인정보보호책임자
06 · Company updates
Updates from Heuron Co.
Recent articles published on Heuron Co.'s official website.
Sep. 2026기술성등급 A·A, 키움증권 손잡고 IPO'속도'인공지능(AI) 의료기기 기업인 휴런이 기업공개(IPO) 준비에 착수할 전망이다. 기술특례상장을 노리고 있는 휴런은 예비심사 청구에 앞서 기술성평가에서 매우 높은 평가를 받았다. 올해 안에 코스닥 예비심사를 청구하고 IPO 절차를 본격화할 예정이다.28일 투자은행(IB) 업계에 따르면 휴런은 최근 한국거래소가 지정한 전문평가기관 두 곳으로부터 기술성에 대해...
Read on Heuron Co.Apr. 2026KSEM 2026KSEM 2026 – Booth #27, 28🗓️ 2026.04.23 - 04.24📍 HICO, Gyeongju, KOREA | 경주 화백컨벤션센터, 대한민국대한응급의학회(KSEM) 2026 연례학술대회에서 휴런을 만나보세요.휴런의 StrawCare Suite™는 뇌졸중 환자의 신속한 분류와 빠른 임상 의사 결정을 지원하는 AI 솔루션으로 비조영 CT ...
Read on Heuron Co.Sep. 2026KCR 2026Heuron of KCR 2026 – Booth #37,38🗓️ 2026.09.09 - 09.12 📍 킨텍스 제2 전시장, 고양시, 대한민국골든타임이 생명인 뇌졸중과 조기 진단이 중요한 퇴행성 뇌질환 영역에서, 의료진의 신속하고 정확한 임상적 의사결정을 돕는 휴런의 솔루션을 오는 9월 9일부터 12일까지 고양 킨텍스 제2전시장, KCR 휴런 부스에서 직...
Read on Heuron Co.휴런 글로벌, 태국 탐마삿대학교병원과 뇌졸중 AI 검증 MOU 체결
Read on Heuron Co.Feb. 2026휴런 글로벌, 태국 탐마삿대학교병원과 뇌졸중 AI 검증 MOU 체결휴런 글로벌, 태국 탐마삿대학교병원과 뇌졸중 AI 검증 MOU 체결동남아 수익화 모델 본격 가동…유료 전환 기반 구축휴런 글로벌(HEURON GLOBAL Co., Ltd.)은 태국의 대표적 국립 대학병원인 탐마삿대학교병원과 뇌졸중 질환 분석을 위한 인공지능(AI) 기술의 유료 사용 전환을 목표로 한 검증 협력 업무협약(M
Read on Heuron Co.07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.